Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
AbbVie says deaths in arthritis trial not linked to drug Ruby Khatun Khatun13 Sept 2017 1:42 PM ISTAbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug,...